Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

A pharmacokinetic natural product-disease-drug interaction: a double hit of silymarin and nonalcoholic steatohepatitis on hepatic transporters in a rat model.

Montonye ML, Tian DD, Arman T, Lynch KD, Hagenbuch B, Paine MF, Clarke JD.

J Pharmacol Exp Ther. 2019 Aug 16. pii: jpet.119.260489. doi: 10.1124/jpet.119.260489. [Epub ahead of print]

2.

Sub-Chronic Microcystin-LR Liver Toxicity in Preexisting Diet-Induced Nonalcoholic Steatohepatitis in Rats.

Arman T, Lynch KD, Montonye ML, Goedken M, Clarke JD.

Toxins (Basel). 2019 Jul 9;11(7). pii: E398. doi: 10.3390/toxins11070398.

3.

Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity.

Clarke JD, Dzierlenga A, Arman T, Toth E, Li H, Lynch KD, Tian DD, Goedken M, Paine MF, Cherrington N.

Toxicon. 2019 Apr 15;162:1-8. doi: 10.1016/j.toxicon.2019.03.002. Epub 2019 Mar 5.

PMID:
30849452
4.

Gene-by-Environment Interaction of Bcrp-/- and Methionine- and Choline-Deficient Diet-Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition.

Toth EL, Li H, Dzierlenga AL, Clarke JD, Vildhede A, Goedken M, Cherrington NJ.

Drug Metab Dispos. 2018 Nov;46(11):1478-1486. doi: 10.1124/dmd.118.082081. Epub 2018 Aug 30.

PMID:
30166404
5.

Broccoli Sprouts Delay Prostate Cancer Formation and Decrease Prostate Cancer Severity with a Concurrent Decrease in HDAC3 Protein Expression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) Mice.

Beaver LM, LÓ§hr CV, Clarke JD, Glasser ST, Watson GW, Wong CP, Zhang Z, Williams DE, Dashwood RH, Shannon J, Thuillier P, Ho E.

Curr Dev Nutr. 2017 Dec 26;2(3):nzy002. doi: 10.1093/cdn/nzy002. eCollection 2018 Mar.

6.

Pediatric Cytochrome P450 Activity Alterations in Nonalcoholic Steatohepatitis.

Li H, Canet MJ, Clarke JD, Billheimer D, Xanthakos SA, Lavine JE, Erickson RP, Cherrington NJ.

Drug Metab Dispos. 2017 Dec;45(12):1317-1325. doi: 10.1124/dmd.117.077644. Epub 2017 Oct 6.

7.

Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease.

Clarke JD, Novak P, Lake AD, Hardwick RN, Cherrington NJ.

Liver Int. 2017 Jul;37(7):1074-1081. doi: 10.1111/liv.13362. Epub 2017 Feb 7.

8.

In vivo cytochrome P450 activity alterations in diabetic nonalcoholic steatohepatitis mice.

Li H, Clarke JD, Dzierlenga AL, Bear J, Goedken MJ, Cherrington NJ.

J Biochem Mol Toxicol. 2017 Feb;31(2). doi: 10.1002/jbt.21840. Epub 2016 Oct 6.

9.

Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir.

Laho T, Clarke JD, Dzierlenga AL, Li H, Klein DM, Goedken M, Micuda S, Cherrington NJ.

Biochem Pharmacol. 2016 Sep 1;115:144-51. doi: 10.1016/j.bcp.2016.07.001. Epub 2016 Jul 2.

10.

Biliary Elimination of Pemetrexed Is Dependent on Mrp2 in Rats: Potential Mechanism of Variable Response in Nonalcoholic Steatohepatitis.

Dzierlenga AL, Clarke JD, Klein DM, Anumol T, Snyder SA, Li H, Cherrington NJ.

J Pharmacol Exp Ther. 2016 Aug;358(2):246-53. doi: 10.1124/jpet.116.234310. Epub 2016 May 27.

11.

Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis.

Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ.

Diabetes. 2015 Sep;64(9):3305-13. doi: 10.2337/db14-1947. Epub 2015 May 27.

12.

Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.

Clarke JD, Cherrington NJ.

Pharmacol Ther. 2015 Jul;151:99-106. doi: 10.1016/j.pharmthera.2015.03.005. Epub 2015 Mar 21. Review.

13.

Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Dzierlenga AL, Clarke JD, Hargraves TL, Ainslie GR, Vanderah TW, Paine MF, Cherrington NJ.

J Pharmacol Exp Ther. 2015 Mar;352(3):462-70. doi: 10.1124/jpet.114.220764. Epub 2014 Dec 15.

14.

Renal xenobiotic transporter expression is altered in multiple experimental models of nonalcoholic steatohepatitis.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Goedken MJ, Cherrington NJ.

Drug Metab Dispos. 2015 Feb;43(2):266-72. doi: 10.1124/dmd.114.060574. Epub 2014 Dec 8.

15.

Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis.

Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ.

Toxicol Sci. 2014 Nov;142(1):45-55. doi: 10.1093/toxsci/kfu156. Epub 2014 Jul 31.

16.

Synergistic interaction between genetics and disease on pravastatin disposition.

Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ.

J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.

17.

Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Clarke JD, Hardwick RN, Lake AD, Canet MJ, Cherrington NJ.

J Pharmacol Exp Ther. 2014 Mar;348(3):452-8. doi: 10.1124/jpet.113.211284. Epub 2014 Jan 8.

18.

Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models.

Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ.

Drug Metab Dispos. 2014 Apr;42(4):586-95. doi: 10.1124/dmd.113.055996. Epub 2014 Jan 2.

19.

Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice.

Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ, Morgan ET.

Drug Metab Dispos. 2014 Apr;42(4):596-602. doi: 10.1124/dmd.113.055525. Epub 2013 Dec 30.

20.

Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis.

Clarke JD, Sharapova T, Lake AD, Blomme E, Maher J, Cherrington NJ.

J Appl Toxicol. 2014 Jun;34(6):726-32. doi: 10.1002/jat.2960. Epub 2013 Nov 12.

Supplemental Content

Loading ...
Support Center